Expression and prognostic value of matriptase in ovarian serous adenocarcinoma

Abstract

Abstract. Previous studies have demonstrated that matriptase is involved in degradation of the extracellular matrix and angiogenesis, and is overexpressed in certain forms of epithelial cancer. The present study aimed to examine matriptase expression in ovarian serous adenocarcinoma, and to investigate its association with clinicopathological characteristics and patient prognosis. Matriptase expression was analyzed in 80 ovarian serous adenocarcinoma and 12 normal ovarian tissue samples by immunohistochemistry. All data were analyzed to evaluate the association between matriptase expression and clinicopathological parameters and overall survival. Immunohistochemistry demonstrated that matriptase protein was significantly overexpressed in the ovarian serous adenocarcinoma tissues compared with the normal ovarian tissues (P=0.0003). Furthermore, matriptase expression was significantly associated with clinical stage (P=0.0077) and lymph node metastasis (P=0.0111). Kaplan-Meier survival curves demonstrated that patients with positive matriptase expression had significantly greater survival times (P=0.0008). Matriptase expression is associated with early stage and a greater survival time; therefore, this protein may function as a novel diagnostic and prognostic marker.

The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells

“…The decrease in matriptase expression levels between time of diagnosis and progression was also not significant. A previous study on ovarian cancer found a positive correlation between matriptase expression, early clinical stage, and increased survival [43]. Another study have demonstrated downregulation of matriptase in human colon adenomas and adenocarcinomas compared to normal tissue [44].…”

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

“…In healthy tissue where protease activity is tightly regulated, the prodomain remains predominantly intact, preventing target binding [18]. However, there is considerable evidence for upregulation of specific proteases in the tumor microenvironment compared to normal non-cancerous tissue [19][20][21][22]. For example, LeBeau et al document active matriptase, a serine protease that can also activate the Probody therapeutics presented in our study, in human colon cancer samples by using an active site monoclonal antibody, whereas normal colon samples show no evidence of this protease activity [19].…”